VR Adviser
Latest statistics and disclosures from Venrock Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, ERAS, ORKA, SYRE, KALV, and represent 55.98% of Venrock Adviser's stock portfolio.
- Added to shares of these 10 stocks: DMRA (+$93M), RLMD (+$34M), TENX (+$27M), OCUL (+$26M), ANL (+$22M), IPSC (+$20M), VOR (+$20M), DNTH (+$15M), KRRO (+$11M), ANRO (+$11M).
- Started 8 new stock positions in DMRA, KRRO, TENX, XFOR, ANRO, RLMD, ANL, IPSC.
- Reduced shares in these 8 stocks: ELVN (-$59M), UPB (-$32M), CTMX (-$26M), ERAS (-$24M), ORIC (-$17M), KALV (-$5.1M), SEPN, CASIF.
- Sold out of its positions in UPB, CASIF.
- Venrock Adviser was a net buyer of stock by $122M.
- Venrock Adviser has $2.7B in assets under management (AUM), dropping by 32.33%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Venrock Adviser
Venrock Adviser holds 33 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 26.7 | $715M | 8.5M | 84.17 |
|
|
| Erasca (ERAS) | 9.9 | $265M | -8% | 16M | 16.18 |
|
| Oruka Therapeutics (ORKA) | 7.6 | $204M | 4.1M | 49.05 |
|
|
| Spyre Therapeutics Com New (SYRE) | 6.9 | $186M | 3.7M | 50.44 |
|
|
| Kalvista Pharmaceuticals (KALV) | 4.9 | $130M | -3% | 6.5M | 20.13 |
|
| Dianthus Therapeutics (DNTH) | 3.7 | $99M | +18% | 1.2M | 83.92 |
|
| Damora Therapeutics Com New (DMRA) | 3.5 | $93M | NEW | 3.6M | 25.90 |
|
| Ocular Therapeutix (OCUL) | 3.3 | $88M | +41% | 10M | 8.47 |
|
| Cogent Biosciences (COGT) | 2.9 | $77M | 2.0M | 38.49 |
|
|
| Miragen Therapeutics (VRDN) | 2.8 | $76M | 3.9M | 19.56 |
|
|
| Savara (SVRA) | 2.8 | $75M | 14M | 5.46 |
|
|
| Enliven Therapeutics (ELVN) | 2.5 | $68M | -46% | 1.7M | 39.20 |
|
| Oric Pharmaceuticals (ORIC) | 2.0 | $55M | -23% | 4.3M | 12.67 |
|
| Vor Biopharma Com New (VOR) | 2.0 | $54M | +56% | 3.0M | 17.84 |
|
| Maze Therapeatics (MAZE) | 1.8 | $48M | +3% | 1.6M | 29.85 |
|
| Cytomx Therapeutics (CTMX) | 1.8 | $47M | -35% | 10M | 4.70 |
|
| Jade Biosciences Com New (JBIO) | 1.7 | $45M | 3.2M | 14.05 |
|
|
| Dyne Therapeutics (DYN) | 1.5 | $39M | 2.2M | 18.13 |
|
|
| Crescent Biopharma (CBIO) | 1.5 | $39M | 2.1M | 18.37 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 1.4 | $38M | +20% | 6.4M | 5.95 |
|
| Relmada Therapeutics (RLMD) | 1.3 | $34M | NEW | 4.8M | 6.96 |
|
| Engene Holdings (ENGN) | 1.2 | $33M | 4.8M | 6.81 |
|
|
| Tenax Therapeutics Com New (TENX) | 1.0 | $27M | NEW | 1.7M | 15.99 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.8 | $22M | NEW | 3.2M | 6.92 |
|
| Century Therapeutics (IPSC) | 0.7 | $20M | NEW | 8.7M | 2.26 |
|
| Cullinan Oncology (CGEM) | 0.7 | $20M | 1.4M | 14.21 |
|
|
| Cybin Com New (HELP) | 0.7 | $19M | 3.9M | 4.80 |
|
|
| Surrozen Com New (SRZN) | 0.7 | $18M | 633k | 29.13 |
|
|
| Septerna (SEPN) | 0.5 | $12M | -17% | 506k | 24.03 |
|
| Korro Bio (KRRO) | 0.4 | $11M | NEW | 1.0M | 11.32 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.4 | $11M | NEW | 500k | 22.48 |
|
| Artiva Biotherapeutics (ARTV) | 0.4 | $10M | 1.6M | 6.44 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 0.1 | $1.4M | NEW | 331k | 4.13 |
|
Past Filings by Venrock Adviser
SEC 13F filings are viewable for Venrock Adviser going back to 2020
- Venrock Adviser 2026 Q1 filed May 15, 2026
- VR Adviser 2025 Q4 filed Feb. 17, 2026
- VR Adviser 2025 Q3 filed Nov. 14, 2025
- VR Adviser 2025 Q2 filed Aug. 14, 2025
- VR Adviser 2025 Q1 filed May 15, 2025
- VR Adviser 2024 Q4 filed Feb. 14, 2025
- VR Adviser 2024 Q3 filed Nov. 14, 2024
- VR Adviser 2024 Q2 filed Aug. 14, 2024
- VR Adviser 2024 Q1 filed May 15, 2024
- VR Adviser 2023 Q4 filed Feb. 14, 2024
- VR Adviser 2023 Q3 filed Nov. 14, 2023
- VR Adviser 2023 Q2 filed Aug. 11, 2023
- VR Adviser 2022 Q2 restated filed May 15, 2023
- VR Adviser 2022 Q3 restated filed May 15, 2023
- VR Adviser 2022 Q4 restated filed May 15, 2023
- VR Adviser 2023 Q1 filed May 15, 2023